Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Phase 2 | DE | 01 Apr 2020 | |
Hodgkin's Lymphoma | Preclinical | DE | 23 Jul 2024 | |
T-Cell Lymphoma | Preclinical | DE | 23 Jul 2024 |